Item 8.01. Other Events.
On August 29, 2012, Exelixis, Inc. (the "Company") was notified by the Food and
Drug Administration (the "FDA") that the Company's new drug application ("NDA")
for cabozantinib as a treatment for patients with progressive, unresectable,
locally advanced, or metastatic medullary thyroid cancer has been removed from
the agenda for the November 8 and November 9, 2012 meeting of the FDA's
Oncologic Drugs Advisory Committee ("ODAC"). As a result, the Company does not
anticipate a discussion of the NDA by ODAC. The previously announced
Prescription Drug User Fee Act (PDUFA) action date remains November 29, 2012.
Add
EXEL to Portfolio
Set Alert
Email to a
Friend